#AACR26 The adenosine pathway is an appealing target given its immunosuppressive role. IPH5201 targets CD39 and has in vitro synergy with...

x.com· @ · X·2026-04-22 20:25· 2026-04-22Score60

Reading

MRD / ctDNA / DTP: from detection to treatment decisions

Nivolumab, pembrolizumab and durvalumab sit in this direction not as new drugs, but because perioperative IO trials wrote ctDNA into the stratification.

Body

#AACR26 The adenosine pathway is an appealing target given its immunosuppressive role. IPH5201 targets CD39 and has in vitro synergy with chemo-immunotherapy. MATISSE leverages that synergy with a combination of perioperative IPH5201 and durvalumab added to neoadjuvant chemo. https://t.co/SXL0HbL1pD

Heat 11 · 10 likes · 1 reply · 0 reposts

Conference abstracts

6547NCT06526104matched by 药名 durvalumab

Phase II single arm study of tremelimumab and durvalumab (MEDI4736) (T300+D) in advanced hepatocellular carcinomas with Child-Pugh-B cirrhosis (STRIDE in CP-B)

Sukeshi Patel Arora, Lorena Fuentes, James Denno, Jennifer Moseley, Brittany M. Altermatt, Elizabeth Diaz, Joshua Ray Smith, Joel Michalek, Lei Zheng

Read the abstract →

6741matched by 药名 pertuzumab

Tertiary lymphoid structure (TLS)-associated immune circuits define response to durvalumab, trastuzumab, and pertuzumab (DTP) in HER2-enriched early breast cancer

Mailin Li, Xen Ping Hoi, Jenying Deng, Junjun Zheng, Rabia Hashmani, Recep Bayraktar, Wei Qian, Jianying Zhou, Jian Guan, Kai Sun, Hanh Mai, Tiffany Sheu, Susan Haley, Mary Schwartz, Sunil Mathur, Stephen T. Wong, Fotis Nikolo, Keith Syson Chan, Polly Niravath, Jenny C. Chang

Read the abstract →

CT230NCT04817826matched by 药名 durvalumab

STRIDE regimen of tremelimumab and durvalumab as non-operative management strategy of microsatellite instability-high (MSI-H) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC): Final results of the cohort 2 of INFINITY study by GONO GI

Alberto Giovanni Leone, Alessandra Raimondi, Paolo Manca, Sabina Murgioni, Giovanni G. Cardellino, Alessandro Bittoni, Antonia Strippoli, Maria Bencivenga, Federica Palermo, Floriana Nappo, Silvio K. Garattini, Thereasa Rich, Gaia Rebecchi, Roberta Fazio, Camilla Damonte, Margherita Ambrosini, Cecilia Villa, Greta Gronchi, Sara Lonardi, Filippo Pietrantonio

Read the abstract →

CT231NCT05742607matched by 代号 IPH5201

Dual CD39 and PD-L1 inhibition: Interim results from the phase 2 MATISSE trial of IPH5201 plus durvalumab (durva) and platinum-based chemotherapy (CT) in patients (pts) with resectable NSCLC

Fabrice Barlesi, Tibor Csoszi, Renata Duchnowska, Thomas Egenod, Laurent Greillier, Amanda Psyrri, Maurice Perol, Herve Lena, Agnes Boyer-Chammard, Veronia Todary, Julien Viotti, Pascale André, Carine Paturel, Markus Jensen

Read the abstract →

Source: x.com · x.com